Unveiling YKL-40, from serum marker to target therapy in glioblastoma

Frontiers in Oncology

Volumn 4 APR, Issue , 2014, Pages

  Iwamoto, Fabio M ^a   Hormigo, Adília ^b  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Glioblastoma; Prognosis; Serum marker; Targeted therapy; YKL 40

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CD133 ANTIGEN; ENDOTHELIN; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCALIN; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; SELECTIN; SYNDECAN 1; TRANSCRIPTION FACTOR RELB; UNCLASSIFIED DRUG; VASCULOTROPIN; YKL 40;

DRUG TARGETING; ENDOTHELIUM CELL; GLIOBLASTOMA; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84901041579     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00090     Document Type: Review

References (36)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 352:987-96. doi:10.1056/NEJMoa043330.
2. Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res (2002) 62:4364-8.
3. Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, et al. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res (2006) 12:5698-704. doi:10.1158/1078-0432.CCR-06-0181.
4. Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, et al. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro Oncol (2011) 13:1244-51. doi:10.1093/neuonc/nor117.
5. Antonelli M, Buttarelli FR, Arcella A, Nobusawa S, Donofrio V, Oghaki H, et al. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas. J Neurooncol (2010) 99:209-15. doi:10.1007/s11060-010-0129-5.
6. Zhang W, Kawanishi M, Miyake K, Kagawa M, Kawai N, Murao K, et al. Association between YKL-40 and adult primary astrocytoma. Cancer (2010) 116:2688-97. doi:10.1002/cncr.25084.
7. Horbinski C, Wang G, Wiley CA. YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas. Int J Clin Exp Pathol (2010) 3:226-37.
8. Shao R, Hamel K, Petersen L, Cao QJ, Arenas RB, Bigelow C, et al. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene (2009) 28:4456-68. doi:10.1038/onc.2009.292.
9. Liu Q, Nguyen DH, Dong Q, Shitaku P, Chung K, Liu OY, et al. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J Neurooncol (2009) 94:1-19. doi:10.1007/s11060-009-9919-z.
10. Liu Y, Ye F, Yamada K, Tso JL, Zhang Y, Nguyen DH, et al. Autocrine endothelin-3/endothelin receptor B signaling maintains cellular and molecular properties of glioblastoma stem cells. Mol Cancer Res (2011) 9:1668-85. doi:10.1158/1541-7786.MCR-10-0563.
11. Ding BS, James D, Iyer R, Falciatori I, Hambardzumyan D, Wang S, et al. Prominin 1/CD133 endothelium sustains growth of proneural glioma. PLoS One (2013) 8:e62150. doi:10.1371/journal.pone.0062150.
12. El Hallani S, Boisselier B, Peglion F, Rousseau A, Colin C, Idbaih A, et al. A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain (2010) 133:973-82. doi:10.1093/brain/awq044.
13. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 17:98-110. doi:10.1016/j.ccr.2009.12.020.
14. Ma X, Yoshimoto K, Guan Y, Hata N, Mizoguchi M, Sagata N, et al. Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma. Neuro Oncol (2012) 14:1153-62. doi:10.1093/neuonc/nos145.
15. Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, Griffin C, et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res (2005) 65:1678-86. doi:10.1158/0008-5472.CAN-04-2921.
16. Pelloski CE, Mahajan A, Maor M, Chang EL, Woo S, Gilbert M, et al. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res (2005) 11:3326-34. doi:10.1158/1078-0432.CCR-04-1765.
17. Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol (2007) 25:2288-94. doi:10.1200/JCO.2006.08.0705.
18. Johansen JS, Lottenburger T, Nielsen HJ, Jensen JE, Svendsen MN, Kollerup G, et al. Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects. Cancer Epidemiol Biomarkers Prev (2008) 17:2603-8. doi:10.1158/1055-9965.EPI-07-2766.
19. Bernardi D, Padoan A, Ballin A, Sartori M, Manara R, Scienza R, et al. Serum YKL-40 following resection for cerebral glioblastoma. J Neurooncol (2012) 107:299-305. doi:10.1007/s11060-011-0762-7.
20. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, et al. A multigene predictor of outcome in glioblastoma. Neuro Oncol (2010) 12:49-57. doi:10.1093/neuonc/nop007.
21. Salvati M, Pichierri A, Piccirilli M, Floriana Brunetto GM, D'Elia A, Artizzu S, et al. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients. J Neurosurg (2012) 117:204-11. doi:10.3171/2012.4.JNS101702.
22. Kavsan VM, Baklaushev VP, Balynska OV, Iershov AV, Areshkov PO, Yusubalieva GM, et al. Gene encoding chitinase 3-like 1 protein (CHI3L1) is a putative oncogene. Int J Biomed Sci (2011) 7:230-7.
23. Saidi A, Javerzat S, Bellahcene A, De Vos J, Bello L, Castronovo V, et al. Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma. Int J Cancer (2008) 122:2187-98. doi:10.1002/ijc.23313.
24. Junker N, Johansen JS, Hansen LT, Lund EL, Kristjansen PE. Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci (2005) 96:183-90. doi:10.1111/j.1349-7006.2005.00026.x.
25. Ku BM, Lee YK, Ryu J, Jeong JY, Choi J, Eun KM, et al. CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells. Int J Cancer (2011) 128:1316-26. doi:10.1002/ijc.25466.
26. Bhat KP, Pelloski CE, Zhang Y, Kim SH, deLaCruz C, Rehli M, et al. Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and -2. FEBS Lett (2008) 582:3193-200. doi:10.1016/j.febslet.2008.08.010.
27. Lee DW, Ramakrishnan D, Valenta J, Parney IF, Bayless KJ, Sitcheran R. The NF-kappaB RelB protein is an oncogenic driver of mesenchymal glioma. PLoS One (2013) 8:e57489. doi:10.1371/journal.pone.0057489.
28. Bhat KP, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, et al. Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell (2013) 24:331-46. doi:10.1016/j.ccr.2013.08.001.
29. Singh SK, Bhardwaj R, Wilczynska KM, Dumur CI, Kordula T. A complex of nuclear factor I-X3 and STAT3 regulates astrocyte and glioma migration through the secreted glycoprotein YKL-40. J Biol Chem (2011) 286:39893-903. doi:10.1074/jbc.M111.257451.
30. Boisselier B, Marie Y, El Hallani S, Kaloshi G, Iershov A, Kavsan V, et al. No association of (-131C- >G) variant of CHI3L1 gene with risk of glioblastoma and prognosis. J Neurooncol (2009) 94:169-72. doi:10.1007/s11060-009-9817-4.
31. Zhang W, Murao K, Zhang X, Matsumoto K, Diah S, Okada M, et al. Resveratrol represses YKL-40 expression in human glioma U87 cells. BMC Cancer (2010) 10:593. doi:10.1186/1471-2407-10-593.
32. Floyd DH, Kefas B, Seleverstov O, Mykhaylyk O, Dominguez C, Comeau L, et al. Alpha-secretase inhibition reduces human glioblastoma stem cell growth in vitro and in vivo by inhibiting Notch. Neuro Oncol (2012) 14:1215-26. doi:10.1093/neuonc/nos157.
33. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol (2011) 29:330-6. doi:10.1200/JCO.2010.30.7744.
34. Francescone RA, Scully S, Faibish M, Taylor SL, Oh D, Moral L, et al. Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem (2011) 286:15332-43. doi:10.1074/jbc.M110.212514.
35. Faibish M, Francescone R, Bentley B, Yan W, Shao R. A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol Cancer Ther (2011) 10:742-51. doi:10.1158/1535-7163.MCT-10-0868.
36. Shao R, Francescone R, Ngernyuang N, Bentley B, Taylor SL, Moral L, et al. Anti-YKL-40 antibody and ionizing irradiation synergistically inhibit tumor vascularization and malignancy in glioblastoma. Carcinogenesis (2014) 35:373-82. doi:10.1093/carcin/bgt380.